| Name | Title | Contact Details |
|---|
Scrippshealth is a Lajolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leading Research into Solving one of the World`s Largest Drivers of Disease: Inflammation
Roche NimbleGen is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.
Morphogenesis is a clinical stage company developing novel cell and gene therapies based on distinct and synergistic technology platforms. Our mission is to change the way chronic diseases are treated by engaging the innate intelligence of the body.